251 286 - Biotech Bayern
251 286 - Biotech Bayern
251 286 - Biotech Bayern
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Contact:<br />
Derek Beggs<br />
Fraunhoferstr. 13<br />
D-82152 Martinsried<br />
Phone: +49 (0) 89 8565 0030<br />
Fax: +49 (0) 89 8565 1333<br />
E-Mail: derek.beggs@bavarian-nordic.com<br />
Internet: www.bavarian-nordic.com<br />
Contact:<br />
Jutta Brenn-Vogt<br />
Edisonstr. 4<br />
D-85716 Unterschleißheim<br />
Phone: +49 (0) 89 31701 0<br />
Fax: +49 (0) 89 31701 177<br />
E-Mail: info_de@baxter.com<br />
Internet: www.baxter.de<br />
Contact:<br />
Patricia Mees<br />
Am Klopferspitz 19a<br />
D-82152 Martinsried<br />
Phone: +49 (0) 89 7294949 0<br />
Fax: +49 (0) 89 7294949 20<br />
E-Mail: jutta_denter@europe.bd.com<br />
Internet: www.bd.com<br />
44<br />
Bavarian Nordic GmbH<br />
BIOTECH THERAPEUTICS & DIAGNOSTICS<br />
Keywords: Drug Development, Vaccines, Infectious Diseases<br />
Bavarian Nordic (BN) is a leading international biopharmaceutical company<br />
developing innovative vaccines to prevent and treat infectious diseases.<br />
The company is capable to meet the growing demand for safe 3rd generation<br />
smallpox vaccines due to its proprietary vaccine technology MVA-BN®. BN was<br />
founded in 1994 and is headquartered in Kvistgaard, Denmark with subsidiary<br />
operations in Martinsried and Berlin, Germany. BN recently founded in the US an<br />
operating company, BN ImmunoTherapeutics Inc., for research and development<br />
of cancer vaccines. The company employs about 180 people and is listed on the<br />
Copenhagen Stock Exchange.<br />
More than 450 healthy and immune compromised subjects so far vaccinated<br />
with MVA-BN®, suggest an excellent safety and efficacy profile of the vector.<br />
Baxter Deutschland GmbH<br />
PHARMA & CHEMICAL INDUSTRY<br />
The Bioscience business of Baxter is represented by the BioScience division.<br />
BioScience produces therapeutic proteins from plasma and through recombinant<br />
methods to treat hemophilia, Immune deficiencies and other blood-related<br />
disorders. These include coagulation factors, immune globulins, albumin,<br />
wound-management products and vaccines. Further divisions of Baxter are<br />
Medication Delivery and Renal. Medication Delivery manufactures products<br />
used to deliver fluids and drugs to patients. The Renal division provides renal<br />
dialysis products and services to support people with kidney failure. The focus<br />
of Baxter Germany is sales and marketing. Manufacturing plants are located at<br />
Plattling (IV solutions) and Halle/Westfalen (Chemotherapeutics). Research<br />
capacities of Baxter Europe are located in Switzerland and Austria. Current R&D<br />
projects aim at new therapeutic proteins and regenerative medicine. Baxter also<br />
co-operates with a number of European and US based <strong>Biotech</strong> companies.<br />
BD Diagnostics<br />
BIOTECH DEVICES & REAGENTS<br />
Keywords: Devices, Automation, Proteomics, Antibody, Ophtalmology,<br />
Fine Chemicals / Reagents, Diabetics<br />
BD (Becton, Dickinson and Company) is a global medical technology company<br />
that is focused on improving drug therapy, enhancing the diagnosis of infectious<br />
diseases and advancing drug discovery. BD manufactures and sells medical<br />
supplies, devices, laboratory instruments, antibodies, reagents and diagnostic<br />
products through its three segments: BD Medical, BD Diagnostics and BD<br />
Biosciences. It serves healthcare institutions, life science researchers, clinical<br />
laboratories, industry and the general public.<br />
BD is headquartered in the United States and has offices in nearly 50 countries<br />
worldwide with more than 26.000 employees.
Change language